Fertility clinics said to lack regulation
By United Press International,
United Press International [cites Marcy Darnovsky]
| 03. 02. 2009
The birth of octuplets in California calls attention to a lack of regulation in the field of assisted reproduction, some experts said.
Although the doctor who supervised in vitro fertilization on the 33-year-old woman who gave birth to octuplets in January is regarded by many in the field as having violated professional norms, U.S. health records indicate a large majority of fertility clinics disregarded implant guidelines in 2006, the Oakland (Calif.) Tribune reported Sunday.
Citing data from the U.S. Centers for Disease Control and Prevention, the newspaper said 80 percent of U.S. fertility clinics in 2006 -- the most recent year for which records are available -- did not follow embryo implant guidelines set in 1999 by the American Society for Reproductive Medicine. The organization advises implanting no more than two embryos in women younger than 35, the report said.
"Assisted reproduction is a multibillion-dollar business," Marcy Darnovsky of the Center for Genetics and Society in Oakland said. "Like other commercial enterprises, it needs rules."
ASRM spokesman Sean Tipton told the newspaper exceptions to the guidelines are permitted, and the...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...